GDF-15 analogues
The brainstem stress signal that causes profound appetite loss — being pushed as an agonist for obesity and blocked as an antagonist for cancer cachexia, with the antagonist side now the more convincing of the two.
Also known as growth differentiation factor 15, MIC-1, NAG-1, GFRAL agonists and antagonists, PF-06946860
Human RCT — Randomised controlled trials in humans, but not an approved product for this use.
The antagonist side has genuine randomised phase 2 human data — ponsegromab improved weight and appetite in cancer cachexia in a placebo-controlled NEJM-published trial, with a 52-week extension. The agonist side for obesity has repeatedly failed to separate weight loss from nausea and has no positive phase 2 readout. Do not let the antagonist evidence launder the agonist claims.
How it works
GDF-15 was orphaned for two decades until 2017, when four groups simultaneously identified GFRAL, expressed almost exclusively in the area postrema and nucleus tractus solitarius, as its receptor; GFRAL then recruits RET for signalling. That anatomical restriction is the whole story: GDF-15 has essentially no direct peripheral metabolic action, and its weight effect is entirely a central anorexia driven through the same circuit that mediates nausea and conditioned taste aversion. Circulating GDF-15 rises with mitochondrial stress, metformin use, pregnancy (it is the primary driver of hyperemesis gravidarum), inflammation and cancer. The agonist path for obesity has been persistently disappointing because the appetite loss is inseparable from the malaise. The antagonist path is stronger: Pfizer's ponsegromab, a GDF-15-neutralising monoclonal antibody, produced dose-dependent weight, appetite, lean-mass and physical-activity gains in a randomised phase 2 trial in cancer cachexia published in the New England Journal of Medicine.
Targets: GFRAL, RET co-receptor, Area postrema, Nucleus tractus solitarius
Dosing
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| Ponsegromab (GDF-15 antagonist) phase 2 dosing — clinical trial context onlyAdministered in clinic. | 100 mg – 400 mg | once every four weeks | subcutaneous |
| GDF-15 agonists for obesityNot applicable. | — | not established | subcutaneous |
- · The phase 2 PROACC-1 trial tested 100, 200 and 400 mg subcutaneously every four weeks in cancer cachexia, with the 400 mg arm carried into the open-label extension. This is an investigational biologic given to cancer patients under supervision, not something with an at-home protocol.
- · Multiple long-acting GDF-15 agonists have entered phase 1 and none has published a dose that separates weight loss from nausea. There is no usable protocol.
Titration
Agonist programmes have all attempted slow titration to outrun the nausea; so far without much success.
Cycling
Not applicable outside clinical trials.
Pharmacology
- Half-life
- Native GDF-15 clears within hours; the therapeutic antibody ponsegromab is dosed once every four weeks, and long-acting Fc-fused agonists are engineered for weekly-or-longer dosing.
- Onset
- Appetite suppression from agonists is near-immediate. In the ponsegromab cachexia trials weight gain accrued over 12 weeks and continued through a 52-week extension.
- Routes
- subcutaneous
- Molecule
- Divergent TGF-beta superfamily cytokine (disulfide-linked homodimer) plus engineered analogues and blocking antibodies
- Sequence length
- 112 amino acids
Handling
- Diluent
- Not applicable
- Lyophilised
- Refrigerated 2-8 C for antibody formulations; do not freeze finished biologic product.
- Reconstituted
- Refrigerated, per clinical protocol.
- Light sensitive
- Yes — keep it out of the light
Mixing
These are recombinant proteins and monoclonal antibodies supplied as clinical-trial material, not lyophilised research peptides.
Side effects
- very commonNausea and vomiting— For agonists this is not a side effect so much as the mechanism itself — GFRAL is the nausea circuit.
- very commonAnorexia and unintended weight loss— Agonist-side effect; the dose-limiting problem.
- commonMuscle wasting with chronic elevation— Sustained high endogenous GDF-15 is what drives cachexia in cancer, heart failure and chronic kidney disease.
Do not use if
- Pregnancy - GDF-15 is the causal driver of hyperemesis gravidarum and raising it further would be actively dangerous.
- Any cachectic or sarcopenic state - agonism here accelerates the exact process you are trying to stop.
- Advanced heart failure or CKD, where GDF-15 is already elevated as a marker of poor prognosis.
Combining it
- cautionsemaglutide — GLP-1 agonists and GDF-15 agonists converge on overlapping brainstem aversion circuits; combining them stacks nausea more than efficacy.
- cautiontirzepatide — Same overlapping area postrema signalling; additive GI intolerance is the expected result.
What to monitor
- · Serum GDF-15 is a validated prognostic biomarker in heart failure and cancer.
- · Weight, lean mass and appetite scores are the trial endpoints that matter.
Legal status
No GDF-15-targeting drug is approved. Ponsegromab is investigational. Recombinant GDF-15 is available as a research reagent only.
References
- Groarke et al. 2024, New England Journal of Medicine — ponsegromab for cancer cachexia, randomised phase 2 (trial)
- Mullican et al. 2017, Nature Medicine — GFRAL identified as the GDF-15 receptor (preclinical)
Mechanism in depth
GDF-15 acts through GFRAL, a receptor expressed almost exclusively in the area postrema and nucleus tractus solitarius of the hindbrain - an unusually clean anatomical restriction that makes it an attractive target. Agonism suppresses appetite; antagonism is being pursued separately for cancer cachexia, where high endogenous GDF-15 drives anorexia and wasting. The same axis is therefore a target in two opposite directions.
What usually goes wrong
The recurring problem in development has been that appetite suppression through this pathway is closely coupled to nausea and aversion, which is precisely the axis that mediates them. Separating the weight effect from the sickness response is the central difficulty, and it is why several programmes have underperformed relative to the preclinical promise.
Receptor targets
- GFRAL, with RET as co-receptor — Varies by analogue
Appetite suppression via hindbrain circuits; the antagonist direction targets cachexia
Genuinely uncertain
- Whether the anorectic effect can be separated from nausea and conditioned taste aversion is the open question for the whole target class.
- Long-term consequences of chronic GFRAL agonism are unknown.
- No GDF-15 analogue is approved.